MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Antares Pharma Company Profile (NASDAQ:ATRS)

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.17 (111.51% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetActions
5/28/2015Jefferies GroupInitiated CoverageBuy$2.15 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015Piper JaffrayInitiated CoverageOverweight$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2014JMP SecuritiesInitiated CoverageOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2014OppenheimerLower Price TargetOutperform$6.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2014Ladenburg ThalmannLower Price Target$6.50 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2013Ladenburg ThalmannBoost Price TargetBuy$5.75 -> $6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2013Jefferies GroupBoost Price TargetBuy$5.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2013Ladenburg ThalmannBoost Price TargetBuy$5.00 -> $5.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha